Sitavis M Tablets 50/850 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
MFDS item code 201505756 · Approved 2015.08.18
This product's status changed to Expired on 2025.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of blood glucose control in patients with type 2 diabetes
This drug works by combining sitagliptin and metformin to effectively control blood sugar levels in patients with type 2 diabetes. When used together with dietary and exercise regimens, it can help manage blood sugar levels consistently. Therefore, it is used as an adjunct treatment for those with type 2 diabetes who find it difficult to manage their blood sugar.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. The initial dose of this medication should be determined based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience of antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - The recommended initial dose of this medication for patients who cannot achieve adequate glycemic control with metformin monotherapy is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from concomitant sitagliptin and metformin therapy to this medication may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take the patient's blood glucose level and current dose into consideration. The dose should be increased gradually to reduce gastrointestinal adverse reactions caused by metformin. When this medication is administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication. Any change in treatment for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication helps control blood sugar. However, it may rarely cause serious allergic reactions, so if symptoms such as skin rash or difficulty in breathing occur, you should immediately stop taking it and consult your doctor. Additionally, it can cause inflammation of the pancreas known as pancreatitis, so if you experience abdominal pain, vomiting, or severe abdominal discomfort, you should quickly visit a hospital. This medication should not be administered to patients with impaired kidney function, severe infections, or heart problems; especially patients with decreased kidney function should consult their doctor before use. You should temporarily discontinue this medication before using iodine-containing contrast agents for tests, and start taking it again only after confirming normal kidney function post-examination. It is safer for women who are pregnant, possibly pregnant, or nursing not to use this medication. During the intake of this medication, be cautious for symptoms of hypoglycemia, especially when taking it alongside other blood sugar-lowering agents, as there may be a higher risk of hypoglycemia, warranting regular blood sugar checks. Moreover, this medication may affect liver and kidney functions, so regular blood tests and kidney function evaluations should be conducted. Alcohol intake may increase the risk of side effects associated with this medication, so it is advisable to avoid drinking during treatment. If you undergo surgery or severe trauma, you should temporarily stop taking this medication and resume it according to the doctor's instructions after recovery. While taking this medication, you must consistently adhere to your dietary and exercise regimens; if any abnormal symptoms occur, consult healthcare professionals immediately.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air from entering, ideally at room temperature between 1 to 30 degrees Celsius. This will help maintain the drug's efficacy and prevent deterioration.
Pink oval film-coated tablet
28 tablets (14 tablets/PTP×2), 56 tablets (14 tablets/PTP×4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.